Massive WHO Study Shows Remdesivir Doesn't Lower COVID-19 Mortality *****UoAeGCkFVB
— zerohedge (@zerohedge) October 15, 2020
Another speedbump has emerged in the drive to produce reliable COVID-19 therapeutics as a highly anticipated WHO drug trial called Solidarity found that Gilead's COVID-19 treatment, remdesivir, had no substantial effect on a COVID-19 patient's chances of survival. It also found that three other therapeutics were similarly ineffective.
The FT called the data a "significant blow" to efforts to find a drug that could help save late-stage COVID-19 patients. What's more, none of the drugs "substantially affected mortality" or reduce the need to ventilate patients.
Other drugs examined in the trial included hydroxychloroquine, lopnavir and interferon regimes. All of them had "little effect" on hospitalized patients.
。。。
